since December 2019, the COVID-19 pandemic is straining hospitals and nephrology services worldwide. Although this disease manifests mostly with pneumonia, acute kidney injury (AKI) is recognized as a common complication in patients with severe manifestations of COVID-19. The pathogenesis of COVID-19 is still unclear but recent evidence supports a multifactorial etiology . Generally, kidney involvement following SARS-CoV-2 infection is proportionate to the gravity of the infection and is commonly diagnosed in hospitalized patients with lung involvement . As in another clinical scenarios, kidney injury is independently associated with morbidity and mortality in patients with SARS-CoV-2 infection [3,4].
The distribution of AKI in patients with COVID-19 is extremely variable across countries . The first reports from China described a low prevalence of AKI in hospitalized patients  but subsequent evidence, coming from the USA and Europe, suggested a higher kidney involvement, especially in the intensive care setting  and among vulnerable patients . Few studies have estimated the rate of AKI in hospitalized patients admitted to non-intensive care units in Italy. It ranges between 13.7-22.6% [9–11] and is similar to the prevalence detected in other European countries (4.5-22%) [12–14]. In order to broaden the knowledge of this phenomenon, we report the data on the prevalence and clinical characteristics of AKI in COVID-19 patients.
La visualizzazione dell’intero documento è riservata a Soci attivi, devi essere registrato e aver eseguito la Login con utente e password.